Nephros Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Für Nephros wird ein Gewinn- und Umsatzwachstum von 44.3% bzw. 13.2% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 41.1% pro Jahr steigen soll.
Wichtige Informationen
44.3%
Wachstumsrate der Gewinne
41.14%
EPS-Wachstumsrate
| Machinery Gewinnwachstum | 16.0% |
| Wachstumsrate der Einnahmen | 13.2% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 07 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for Nephros, Inc. ( NASDAQ:NEPH ) shareholders, with its shares surging 15% to US$3.52 in...Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders might have noticed that Nephros, Inc. ( NASDAQ:NEPH ) filed its quarterly result this time last week. The...Recent updates
NEPH: Index Additions And Water Filtration Leadership Will Support Future Upside
Analysts trimmed their fair value estimate for Nephros from $7 to $6, citing a higher future P/E assumption of about 50x and a weaker profit margin outlook. They also highlight the company's five nanometer ultrafilter and indicate they would like to see revenue growth trends improve further before becoming more positive on the stock.
NEPH: Index Additions And Mergers Will Shape Future Trading Profile
Analysts now see Nephros shares fairly valued closer to $4.00 per share, aligning with a new $4 price target that reflects confidence in its ultrafilter technology, while also recognizing that recent gains already capture much of the anticipated growth until revenue expansion re-accelerates above 20%. What’s in the News for Nephros Nephros is actively seeking acquisitions, merger partners, and business development investments, with management indicating an interest in opportunities that they view as offering a significantly higher return on investment, source: Nephros investor event.Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for Nephros, Inc. ( NASDAQ:NEPH ) shareholders, with its shares surging 15% to US$3.52 in...Is Nephros, Inc. (NASDAQ:NEPH) Potentially Undervalued?
Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it saw a decent share price growth of 19% on the...Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28%
Nephros, Inc. ( NASDAQ:NEPH ) shareholders won't be pleased to see that the share price has had a very rough month...Is It Time To Consider Buying Nephros, Inc. (NASDAQ:NEPH)?
Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it received a lot of attention from a...Nephros (NASDAQ:NEPH) Is Experiencing Growth In Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Why Investors Shouldn't Be Surprised By Nephros, Inc.'s (NASDAQ:NEPH) 27% Share Price Surge
Nephros, Inc. ( NASDAQ:NEPH ) shareholders would be excited to see that the share price has had a great month, posting...At US$4.26, Is Nephros, Inc. (NASDAQ:NEPH) Worth Looking At Closely?
Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it saw a significant share price rise of 47...It's Down 26% But Nephros, Inc. (NASDAQ:NEPH) Could Be Riskier Than It Looks
NasdaqCM:NEPH 1 Year Share Price vs Fair Value Explore Nephros's Fair Values from the Community and select yours...Nephros, Inc.'s (NASDAQ:NEPH) 79% Jump Shows Its Popularity With Investors
Despite an already strong run, Nephros, Inc. ( NASDAQ:NEPH ) shares have been powering on, with a gain of 79% in the...Should You Think About Buying Nephros, Inc. (NASDAQ:NEPH) Now?
Nephros, Inc. ( NASDAQ:NEPH ), is not the largest company out there, but it led the NASDAQCM gainers with a relatively...Investors Still Aren't Entirely Convinced By Nephros, Inc.'s (NASDAQ:NEPH) Revenues Despite 32% Price Jump
Nephros, Inc. ( NASDAQ:NEPH ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)
There wouldn't be many who think Nephros, Inc.'s ( NASDAQ:NEPH ) price-to-sales (or "P/S") ratio of 1.2x is worth a...We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, although...Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders might have noticed that Nephros, Inc. ( NASDAQ:NEPH ) filed its quarterly result this time last week. The...After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar
Nephros, Inc. ( NASDAQ:NEPH ) shares have continued their recent momentum with a 40% gain in the last month alone. The...At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?
Nephros, Inc. ( NASDAQ:NEPH ), might not be a large cap stock, but it received a lot of attention from a substantial...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 29 | 4 | N/A | N/A | 1 |
| 12/31/2027 | 25 | 2 | 3 | N/A | 2 |
| 12/31/2026 | 22 | 1 | -1 | N/A | 1 |
| 6/30/2026 | 21 | 2 | N/A | N/A | N/A |
| 3/31/2026 | 19 | 1 | 0 | 0 | N/A |
| 12/31/2025 | 19 | 1 | 2 | 2 | N/A |
| 9/30/2025 | 18 | 1 | 3 | 3 | N/A |
| 6/30/2025 | 17 | 1 | 2 | 2 | N/A |
| 3/31/2025 | 16 | 1 | 0 | 1 | N/A |
| 12/31/2024 | 14 | 0 | -1 | 0 | N/A |
| 9/30/2024 | 14 | -1 | -2 | -2 | N/A |
| 6/30/2024 | 14 | -1 | -1 | -1 | N/A |
| 3/31/2024 | 14 | -1 | 0 | 0 | N/A |
| 12/31/2023 | 14 | -2 | 1 | 1 | N/A |
| 9/30/2023 | 14 | -2 | 1 | 1 | N/A |
| 6/30/2023 | 12 | -3 | 0 | 0 | N/A |
| 3/31/2023 | 12 | -3 | -1 | -1 | N/A |
| 12/31/2022 | 10 | -5 | -3 | -3 | N/A |
| 9/30/2022 | 10 | -5 | -4 | -3 | N/A |
| 6/30/2022 | 10 | -4 | -4 | -4 | N/A |
| 3/31/2022 | 10 | -4 | -3 | -3 | N/A |
| 12/31/2021 | 10 | -3 | -2 | -1 | N/A |
| 9/30/2021 | 10 | -3 | -3 | -3 | N/A |
| 6/30/2021 | 9 | -4 | -4 | -4 | N/A |
| 3/31/2021 | 9 | -4 | -5 | -5 | N/A |
| 12/31/2020 | 9 | -5 | -7 | -7 | N/A |
| 9/30/2020 | 9 | -4 | -5 | -5 | N/A |
| 6/30/2020 | 10 | -4 | -4 | -4 | N/A |
| 3/31/2020 | 11 | -3 | N/A | -3 | N/A |
| 12/31/2019 | 10 | -3 | N/A | -2 | N/A |
| 9/30/2019 | 9 | -4 | N/A | -3 | N/A |
| 6/30/2019 | 7 | -4 | N/A | -4 | N/A |
| 3/31/2019 | 6 | -3 | N/A | -4 | N/A |
| 12/31/2018 | 6 | -3 | N/A | -4 | N/A |
| 9/30/2018 | 5 | -1 | N/A | -1 | N/A |
| 6/30/2018 | 5 | -1 | N/A | -1 | N/A |
| 3/31/2018 | 4 | -2 | N/A | 0 | N/A |
| 12/31/2017 | 4 | -1 | N/A | 0 | N/A |
| 9/30/2017 | 3 | -3 | N/A | -2 | N/A |
| 6/30/2017 | 3 | -3 | N/A | -2 | N/A |
| 3/31/2017 | 2 | -3 | N/A | -2 | N/A |
| 12/31/2016 | 2 | -3 | N/A | -2 | N/A |
| 9/30/2016 | 2 | -3 | N/A | -3 | N/A |
| 6/30/2016 | 2 | -3 | N/A | -3 | N/A |
| 3/31/2016 | 2 | -4 | N/A | -3 | N/A |
| 12/31/2015 | 2 | -3 | N/A | -4 | N/A |
| 9/30/2015 | 2 | -3 | N/A | -3 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NEPHDas prognostizierte Gewinnwachstum (44.3% pro Jahr) liegt über der Sparquote (3.7%).
Ertrag vs. Markt: NEPHDie Erträge des Unternehmens (44.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.8% pro Jahr).
Hohe Wachstumserträge: NEPHEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: NEPHDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.9% pro Jahr).
Hohe Wachstumseinnahmen: NEPHDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NEPH in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/11 21:33 |
| Aktienkurs zum Tagesende | 2026/08/11 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Nephros, Inc. wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Robert Wasserman | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Anthony Vendetti | Maxim Group |